Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 16/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.42 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.39 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25804693 | 0.87 | ATF4 (0.50) | ATF4 | |
| SCHEMBL20992524 | 0.86 | ATF4 (0.51) | ATF4 | |
| SCHEMBL20992410 | 0.85 | ATF4 (0.50) | ATF4ROCK2ROCK1 | |
| SCHEMBL19568607 | 0.85 | ATF4 (0.50) | ATF4 | |
| SCHEMBL19568902 | 0.85 | ATF4 (0.49) | ATF4ROCK2ROCK1KCNQ3KCNQ2 | |
| SCHEMBL20992611 | 0.85 | ATF4 (0.52) | ATF4 | |
| SCHEMBL19556040 | 0.85 | ATF4 (0.60) | ATF4ROCK2ROCK1KCNQ3KCNQ2 | |
| SCHEMBL19569510 | 0.85 | ATF4 (0.49) | ATF4 | |
| SCHEMBL25812710 | 0.84 | ATF4 (0.53) | ATF4 | |
| SCHEMBL25796703 | 0.84 | ATF4 (0.53) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135772-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135772-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | ATF4 1/4885ROCK2 2906/4885ROCK1 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.